Statistics

	Views
Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement	37

Select a period of time:

	Views
Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement	32

RUNA digital repository